What's new

Opinion/decision on a Paediatric investigation plan (PIP): Exparel liposomal, bupivacaine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pain, PIP number: P/0021/2024

Opinion/decision on a Paediatric investigation plan (PIP): Exparel liposomal, bupivacaine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pain, PIP number: P/0021/2024

Mar 24, 2025 - 16:52
 0
Opinion/decision on a Paediatric investigation plan (PIP): Exparel liposomal, bupivacaine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pain, PIP number: P/0021/2024
Opinion/decision on a Paediatric investigation plan (PIP): Exparel liposomal, bupivacaine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pain, PIP number: P/0021/2024
Read More

Tags:

Previous Article

UK Government's 'Tunnel Vision' Growth Approach Risking Nationwide Job Opportuni...

Next Article

Human medicines European public assessment report (EPAR): Seladelpar Gilead, Sel...

Related Posts

Human medicines European public assessment report (EPAR): Rozlytrek, entrectinib, Date of authorisation: 31/07/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 14, 2025  0

Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 27, 2025  0

EMA human resources strategy: Priorities 2023-2025

Feb 9, 2025  0